论文部分内容阅读
目的：评价国产重组链激酶（ｒ－ＳＫ）经静脉溶栓治疗急性心肌梗塞（ＡＭＩ）的临床疗效，并观察其不良反应。方法：本院２年间经ｒ－ＳＫ静脉溶栓治疗ＡＭＩ患者１１６例，其中５８例行９０分钟冠状动脉造影。结果：临床血管再通率为６９．０％，血管通畅率为７０．７％，其中心肌梗塞溶栓治疗临床试验（ＴＩＭＩ）３级血流占４３．１％。不良反应发生率：过敏反应６．９％，低血压６．０％，黄疸１．７％，出血１０．３％。９．５％患者急性期发生心力衰竭，与延迟溶栓、血管未通有关。急性期死亡率２．６％。结论：国产ｒ－ＳＫ治疗ＡＭＩ有效且较安全。
Objective: To evaluate the clinical efficacy of domestic recombinant streptokinase (r-SK) in the treatment of acute myocardial infarction (AMI) by intravenous thrombolysis and to observe its adverse reactions. Methods: 116 cases of AMI were treated with r-SK intravenous thrombolysis in our hospital in 2 years, of which 58 cases underwent 90-minute coronary angiography. Results: The rate of clinical recanalization was 69.0% and the rate of vascular patency was 70.7%. Grade III blood flow in TIMI was 43.1%. The incidence of adverse reactions: 6.9% of allergic reactions, hypotension 6.0%, jaundice 1.7%, bleeding 10.3%. 9.5% of patients with acute heart failure, delayed thrombolysis, vascular failure. Acute phase mortality 2.6%. Conclusion: Domestic r-SK treatment of AMI effective and more secure.